8-KOther EventsExhibits & Filings

AGILENT TECHNOLOGIES, INC. 8-K Report, Corporate Update (Sep 10, 2012)

Filed September 10, 2012For Securities:A

Summary

Agilent Technologies, Inc. filed this Current Report on Form 8-K primarily to incorporate revisions into its previously filed Annual Report on Form 10-K for the year ended October 31, 2011. These revisions are necessary due to the formation of a new operating segment, 'Diagnostics and Genomics,' which was created in the third fiscal quarter of 2012. This new segment comprises a portion of the existing life sciences business and the acquired Dako business. Following this reorganization, Agilent now reports four distinct business segments: Electronic Measurement, Chemical Analysis, Life Sciences, and the newly formed Diagnostics and Genomics. The company has restated historical segment numbers for the Life Sciences and Diagnostics and Genomics segments to align with this new structure. Investors should note that this 8-K filing does not include new financial information or updates on subsequent events beyond the segment structure change; for more current information, reference Agilent's Form 10-Q for the period ending July 31, 2012, and other SEC filings.

Key Highlights

  • 1Agilent Technologies has reorganized into four business segments by creating a new 'Diagnostics and Genomics' segment.
  • 2The new segment was formed from a portion of the existing Life Sciences business and the acquisition of Dako.
  • 3Historical segment financial data for Life Sciences and Diagnostics and Genomics have been recast to reflect the new structure.
  • 4This 8-K filing is for incorporation into future registration statements.
  • 5Revisions are made to specific items within the 2011 Form 10-K, including Business, Risk Factors, Properties, MD&A, and Financial Statements.
  • 6This filing does not update financial results or provide information on events subsequent to the Form 10-K, apart from segment structure adjustments.

Frequently Asked Questions

The main purpose of this 8-K filing is to inform investors about the formation of a new operating segment, 'Diagnostics and Genomics,' and to incorporate revised disclosures related to this change into Agilent's prior Form 10-K filing for the fiscal year ended October 31, 2011.

Agilent has reorganized its business segments from three to four. The new structure includes the Electronic Measurement, Chemical Analysis, Life Sciences, and the newly created Diagnostics and Genomics segments. Historical segment data has been restated to conform to this new reporting structure.

No, this filing primarily addresses a change in business structure and segment reporting. It does not contain updated financial performance information or details on events occurring after the filing of the Form 10-K. For the most current financial performance, investors should refer to Agilent's Form 10-Q filing for the quarter ended July 31, 2012.

The Dako acquisition is directly linked to the formation of the new 'Diagnostics and Genomics' segment. This new segment was created by combining a part of Agilent's existing Life Sciences business with the recently acquired Dako business.